Juang Yah Ru

Research Fellow

Email e0323980@u.nus.edu; yahru.j@nus.edu.sg

JUANG Yah Ru

Chronic diseases continue to impose substantial health and economic burdens worldwide. Population heterogeneity, inequities in healthcare access, and variations in healthcare utilisation present ongoing challenges for early detection, effective disease management, and equitable care.

Dr. Juang’s research addresses these challenges through the application of population health analytics, epidemiology, and health services research. Her work integrates real-world healthcare data, advanced statistical modelling, and health economic evaluation to generate evidence that informs precision prevention and early detection. By translating population-level evidence into clinical and policy decision-making, her research aims to improve health outcomes and support more efficient, equitable healthcare systems.

Affiliation

  • NUS Saw Swee Hock School of Public Health

Research Areas

  • Population health analytics
  • Chronic disease epidemiology (Cancer and respiratory diseases)
  • Precision prevention, early detection, and risk prediction
  • Health economics and value-based care

Academic/Professional Qualifications

  • Doctor of Philosophy (Public Health), National University of Singapore (2026)
  • Bachelor of Sciences (Life Sciences), National University of Singapore (2022)

Career History

  • Research Fellow, Saw Swee Hock School of Public Health, NUS (2026-present)
  • Research Associate, Saw Swee Hock School of Public Health, NUS (2025-2026)
  • Research Assistant, Saw Swee Hock School of Public Health, NUS (2023-2025)

Professional/Consulting Activities

  • International Agency for Research on Cancer (IARC/WHO)

Selected Publications

  • Juang YR, Chen W, Ng AJH, et al. Development and validation of lung cancer risk prediction models in the Singapore Chinese population. Clinical Lung Cancer. 2026 May. https://doi.org/10.1016/j.cllc.2026.04.014.
  • Low A*, Juang YR*, Ivan FX, et al. Bacterial taxa associated with lung cancer cases in Southeast Asians: A pilot case-control study. Cell Oncol (Dordr). 2026 Apr 10;49(2):69. doi: 10.1007/s13402-026-01193-7.
  • Juang YR*, Lim LHM*, Chotirmall SH, et al. Projecting the 20-Year Healthcare Resource Burden of Asthma and COPD Multimorbidity: Insights from Singapore for Integrated Chronic Respiratory Care in South-East Asia. npj Primary Care Respiratory Medicine (2026). https://doi.org/10.1038/s41533-026-00502-9.
  • Juang YR*, Lim LHM*, Chotirmall SH, et al. Healthcare Costs and Trends of Multimorbidity in COPD Patients: A Population-Based Study in Singapore. International Journal of Chronic Obstructive Pulmonary Disease. 2026 Feb 17;21:563620. doi: 10.2147/COPD.S563620.
  • Juang YR, Hu M, Hui M, Seow A, Tan IBH, Chong DQ, Chee CE, Seow WJ. Trends in lung cancer incidence and stage at diagnosis in Singapore: a population-based joinpoint regression analysis by age, sex, and smoking status. Lancet Reg Health West Pac. 2025 Dec 19;66:101779. doi: 10.1016/j.lanwpc.2025.101779.
  • Juang YR, Ang L, Seow WJ. Predictive performance of risk prediction models for lung cancer incidence in Western and Asian countries: a systematic review and meta-analysis. Sci Rep. 2025 Mar 4;15(1):4259. doi: 10.1038/s41598-024-83875
  • Ho OTW, Lim BSY, Juang YR, Lim RQQ, Tan JL. SMARCB1 deficient sinonasal carcinoma: an updated systematic review and survival analysis. J Laryngol Otol. 2026 Mar 24:1-29. doi: 10.1017/S0022215126104605.
  • Lim LHM, Juang YR, Chotirmall SH, Tan KB, Koh MS, Abisheganaden JA, et al. Economic burden of asthma multimorbidity in Singapore: Shadow costs of steroid use. World Allergy Organization Journal. 2025;18(12):101146. doi: 10.1016/j.waojou.2025.101146.
  • Chen W, Butani D, Wang Y, Bouttell J, Juang YR, Scuffham P, et al. Development of the PICCOTEAM Reference Case for Economic Evaluation of Precision Medicine. International journal of health policy and management vol. 14 (2025): 8756. doi:10.34172/ijhpm.8756
  • Sadatsafavi M, Tran TN, Scelo G,… Juang YR,…Price DB. Prevention of Cardiovascular and Other Systemic Adverse Outcomes in Patients with Asthma Treated with Biologics. Am J Respir Crit Care Med. 2025 Jul;211(7):1165-1174. doi: 10.1164/rccm.202501-0246OC.
  • Lim LHM, Juang YR, Liew MF, et al. Guideline-based asthma treatment in Asia: Insights from a robust time-in-state model. J Allergy Clin Immunol Glob. 2025 Jul 1;4(4):100531. doi: 10.1016/j.jacig.2025.100531.
  • Yadav CP, Lim LHM, Price DB, …, Juang YR,….Chen W. Interactive Pathways of Key Prognostic Factors in Severe Asthma: A Bayesian Network Comparison of Trials & Real-World Data. Chest. 2026 May;169(5):1183-1197. doi: 10.1016/j.chest.2026.01.009.
  • Yadav CP, Chakraborty A, Price DB, Lim LH, Juang YR,…Chen W. Prediction pathway for severe asthma exacerbations: a Bayesian Network analysis. Chest. 2025 May 19:S0012-3692(25)00647-6. doi: 10.1016/j.chest.2025.04.046.
  • Chen W, Tran TN, Townend J,…Juang YR,…Price DB. Impact of biologics initiation on oral corticosteroid use in the International Severe Asthma Registry and the Optimum Patient Care Research Database: a pooled analysis of real-world data. J Allergy Clin Immunol Pract. 2025 Apr 26:S2213-2198(25)00390-3. doi: 10.1016/j.jaip.2025.04.032.

Selected Publications

Back to Faculty Directory
Scroll to Top